Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2017

Open Access 01-12-2017 | Research

Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life

Authors: Silviya Mihaylova Novakova, Maria Toncheva Staevska, Plamena Ivanova Novakova, Manuela Dimitrova Yoncheva, Maria Stoykova Bratoycheva, Nina Mihaylova Musurlieva, Valeri Dimitrov Tzekov, Dimitar Georgiev Nicolov

Published in: Health and Quality of Life Outcomes | Issue 1/2017

Login to get access

Abstract

Background

Along with its high prevalence, the burden of allergic rhinitis rests upon the serious impact on quality of life of patients. Allergic rhinitis is associated with impairments in daily activities, work and school performance, and practical problems. Patients suffer from sleep disorders and emotional problems. Тhe advantages of sublingual immunotherapy on quality of life have only recently begun to emerge. The objective of this prospective real-life study was to evaluate the effect of a three-year course of sublingual immunotherapy with house dust mite (HDM) and grass pollen extracts on quality of life in adults with allergic rhinitis.

Methods

A total number of 191 adult patients [105 (54,979%) men; mean age 27.3 years (SD-6.14)] with moderate to severe allergic rhinitis and clinically relevant sensitization to house dust mites or grass pollen were prospectively evaluated in the course of management of their disease. Health-related quality of life was assessed by Rhinoconjunctivitis Quality of Life Questionnaire at baseline and after three-year course of sublingual immunotherapy.

Results

The mean overall Qol score assessed at baseline and at the end of the third year of treatment decreased significantly in patients treated with HDM extract (from 2.95 to 0.76) as well as with Grass pollen extract (from 2.83 to 1.22) (р < 0.001). The improvements in treated with HDM extract were as followed: activities – 3.52 to 0.68; sleep- 2.48 to 0.31; general problems – 1.79 to 0.49; practical problems – 3.57 to 0.68; nasal symptoms – 3.91 to 0.74; eye symptoms – 2.92 to 0.39; emotions – 3.03 to 0.39. The improvements in grass pollen group were: activities – 3.68 to 1.69; sleep- 1.85 to 0.84; general problems – 1.74 to 0.97; practical problems – 3.52 to 1.37; nasal symptoms – 3.72 to 1.57; eye symptoms – 3.58 to 1.3; emotions – 2.48 to 1.19.

Conclusion

Our study conducted in real life provided evidence that a three-year course of SLIT with HDM extract as well as with grass pollen extract significantly increased QoL in patients with allergic rhinitis.
Literature
1.
go back to reference Pawankar R, Sanchez-Borges, Bonini S, et al. The burden of allergic diseases. In: WAO White book on allergy 2013. p. 27-33. Pawankar R, Sanchez-Borges, Bonini S, et al. The burden of allergic diseases. In: WAO White book on allergy 2013. p. 27-33.
2.
go back to reference Bousquet J, Anto JM, Demoli P, et al. Severe chronic allergic (and related) diseases: a uniform approach – a MeDALL – G2ALLEN – ARIA Position Paper. Int Arch Allergy Immunol. 2012;158:216–31.CrossRefPubMed Bousquet J, Anto JM, Demoli P, et al. Severe chronic allergic (and related) diseases: a uniform approach – a MeDALL – G2ALLEN – ARIA Position Paper. Int Arch Allergy Immunol. 2012;158:216–31.CrossRefPubMed
3.
go back to reference Baiardini I, Braido F, Brandi S, et al. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol. 2006;97:419–28.CrossRefPubMed Baiardini I, Braido F, Brandi S, et al. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol. 2006;97:419–28.CrossRefPubMed
4.
go back to reference Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117:158–62.CrossRefPubMed Bousquet J, Neukirch F, Bousquet PJ, et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol. 2006;117:158–62.CrossRefPubMed
5.
go back to reference Bousquet J, Khalttaev N, Cruzz AA et al. Allergic rhinitis and impact on asthma (ARIA) 2008 update. Allergy. 2008;86(63 Suppl):8-160. Bousquet J, Khalttaev N, Cruzz AA et al. Allergic rhinitis and impact on asthma (ARIA) 2008 update. Allergy. 2008;86(63 Suppl):8-160.
6.
go back to reference Canonica G, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(6):3–52. Canonica G, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(6):3–52.
7.
go back to reference Brozek J, Bousquet J, Baena–Cagnani C, et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2010 Revision. J Allergy Clin Immunol. 2010;9:1–153. Brozek J, Bousquet J, Baena–Cagnani C, et al. Allergic Rhinitis and its impact on Asthma (ARIA) 2010 Revision. J Allergy Clin Immunol. 2010;9:1–153.
8.
go back to reference Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854–67.CrossRefPubMed Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854–67.CrossRefPubMed
9.
go back to reference Laury A, Schlosser R, Wise S. Sullingual immunotherapy and quality of life. Curr Opin Otolaryngol Head Neck Sur. 2013;21:252–5.CrossRef Laury A, Schlosser R, Wise S. Sullingual immunotherapy and quality of life. Curr Opin Otolaryngol Head Neck Sur. 2013;21:252–5.CrossRef
10.
go back to reference Blias M, Maloney J, Notle H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American children and adolescents. J Allergy Clin Immunol. 2011;127:64–71.CrossRef Blias M, Maloney J, Notle H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American children and adolescents. J Allergy Clin Immunol. 2011;127:64–71.CrossRef
11.
go back to reference Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127:72–80.CrossRefPubMed Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127:72–80.CrossRefPubMed
12.
go back to reference Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128:559–66.CrossRefPubMed Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128:559–66.CrossRefPubMed
13.
go back to reference Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: comfirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–25.CrossRefPubMed Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: comfirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–25.CrossRefPubMed
14.
go back to reference Passalacqual G, Pasquali M, Ariano R, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006;61:849–54.CrossRef Passalacqual G, Pasquali M, Ariano R, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006;61:849–54.CrossRef
15.
go back to reference Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis. Ann Allergy Asthma Immunol. 2015;114:134–40.CrossRefPubMed Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis. Ann Allergy Asthma Immunol. 2015;114:134–40.CrossRefPubMed
16.
go back to reference Bosquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67:18–24.CrossRef Bosquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67:18–24.CrossRef
17.
go back to reference Juniper E, Guyatt G. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77–83.CrossRefPubMed Juniper E, Guyatt G. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77–83.CrossRefPubMed
18.
go back to reference Juniper E, Guyatt G, Dolovich J. Assessment of quality of life in adolescents with allergic rhiniconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994;93:413–22.CrossRefPubMed Juniper E, Guyatt G, Dolovich J. Assessment of quality of life in adolescents with allergic rhiniconjunctivitis: Development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994;93:413–22.CrossRefPubMed
19.
go back to reference Novakova S, Dimitrova D, Masaldjieva R, et al. Validation of the questionnaire for assessment the control of allergic rhinitis in Bulgarian language. Thorac Med. 2014;1:43–9. Novakova S, Dimitrova D, Masaldjieva R, et al. Validation of the questionnaire for assessment the control of allergic rhinitis in Bulgarian language. Thorac Med. 2014;1:43–9.
20.
go back to reference Ridolo F, Caffarelli C, Olivieri E, et al. Quality of sleep in allergic children and their parents. Allergol Immunopathol. 2015;43(2):180–4.CrossRef Ridolo F, Caffarelli C, Olivieri E, et al. Quality of sleep in allergic children and their parents. Allergol Immunopathol. 2015;43(2):180–4.CrossRef
22.
go back to reference Braido F, Bousquet P, Brzoza Z, et al. Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper. Allergy. 2010;65:959–68.CrossRefPubMed Braido F, Bousquet P, Brzoza Z, et al. Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA2LEN taskforce position paper. Allergy. 2010;65:959–68.CrossRefPubMed
23.
go back to reference Ciprandi G, Klersy C, Girillo I, et al. Quality of life in allergic rhinitis: relationship with clinical, immunological and functional aspects. Clin Exp Allergy. 2007;37:1528–35.PubMed Ciprandi G, Klersy C, Girillo I, et al. Quality of life in allergic rhinitis: relationship with clinical, immunological and functional aspects. Clin Exp Allergy. 2007;37:1528–35.PubMed
24.
go back to reference Bousquet J, Bachert C, Canonica GW. Uncontrolled allergic rhinitis during treatment and an impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126:666–8.CrossRefPubMed Bousquet J, Bachert C, Canonica GW. Uncontrolled allergic rhinitis during treatment and an impact on quality of life: a cluster randomized trial. J Allergy Clin Immunol. 2010;126:666–8.CrossRefPubMed
25.
go back to reference Eifan AO, Calderon MA, Duhram SR, et al. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanism in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543–56.CrossRefPubMed Eifan AO, Calderon MA, Duhram SR, et al. Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanism in allergic rhinitis and asthma. Expert Opin Biol Ther. 2013;13(11):1543–56.CrossRefPubMed
26.
go back to reference Bousquet P, Demolt P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393–400.CrossRefPubMed Bousquet P, Demolt P, Devillier P, et al. Impact of allergic rhinitis symptoms on quality of life in primary care. Int Arch Allergy Immunol. 2013;160:393–400.CrossRefPubMed
27.
go back to reference Ciprandi G, Cadario G, Valle C. Sublingual Immunotherapy in polysensitized patient: Effect on Quality of life. J Investing Allergol Clin Immunol. 2010;20:274–9. Ciprandi G, Cadario G, Valle C. Sublingual Immunotherapy in polysensitized patient: Effect on Quality of life. J Investing Allergol Clin Immunol. 2010;20:274–9.
28.
go back to reference Durham S, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Aller Clin Immunol. 2016;137:339–49.CrossRef Durham S, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Aller Clin Immunol. 2016;137:339–49.CrossRef
29.
go back to reference Burks AW, Calderon M, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immununology/ European Academy of Allergy and Clinical Immunology/ PRACTAL consensus. J Allergy Clin Immunol. 2013;131:1288–96.CrossRefPubMed Burks AW, Calderon M, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immununology/ European Academy of Allergy and Clinical Immunology/ PRACTAL consensus. J Allergy Clin Immunol. 2013;131:1288–96.CrossRefPubMed
Metadata
Title
Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life
Authors
Silviya Mihaylova Novakova
Maria Toncheva Staevska
Plamena Ivanova Novakova
Manuela Dimitrova Yoncheva
Maria Stoykova Bratoycheva
Nina Mihaylova Musurlieva
Valeri Dimitrov Tzekov
Dimitar Georgiev Nicolov
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2017
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-017-0764-z

Other articles of this Issue 1/2017

Health and Quality of Life Outcomes 1/2017 Go to the issue